Missing content? – Request curation!
Request curation for specific Genes, variants, or PubMed publications.
Have questions, comments or suggestions? - Let us know!
Email us at : firstname.lastname@example.org
|Drug Name||Trade Name||Synonyms||Drug Classes||Drug Description|
|ABBV-181||ABBV181|ABBV 181||Immune Checkpoint Inhibitor 94 PD-L1/PD-1 antibody 63||ABBV-181 is a monoclonal antibody that targets PD-1 (PDCD1) and inhibits binding of the PD-L1 (CD274) ligand, potentially resulting in enhanced anti-tumor immune response (NCI Drug Dictionary).|
|ABT-165||DLL4 Antibody 6 VEGF Antibody 11||ABT-165 is a bispecific antibody that binds to and inhibits signaling of both DLL4 and VEGF, which results in tumor growth inhibition (PMID: 29592882).|
|Paclitaxel||Taxol||7-Epipaclitaxel||Antimicrotubule Agent 12 BCL2 Family Inhibitor 6||Taxol (paclitaxel) binds to tubulin to inhibit microtubule disassembly, which results in decreased cell division, and also binds to the anti-apoptotic factor Bcl-2, promoting apoptosis (NCI Drug Dictionary).|
|Molecular Profile||Indication/Tumor Type||Response Type||Therapy Name||Approval Status||Evidence Type||Efficacy Evidence||References|
|Clinical Trial||Phase||Therapies||Title||Recruitment Status|
|NCT01946074||Phase I||ABT-165 ABBV-181 + ABT-165 + Paclitaxel ABBV-181 + ABT-165 ABT-165 + Paclitaxel ABT-165 + Fluorouracil + Irinotecan + Leucovorin||A Study of ABT-165 in Subjects With Solid Tumors||Active, not recruiting|